This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CERC Cerecor (CERC) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisTrendsBuy This Stock About Cerecor Stock (NASDAQ:CERC) Get Cerecor alerts:Sign Up Key Stats Today's Range$14.11▼$16.6650-Day Range$2.06▼$3.2452-Week Range$1.98▼$4.50Volume1.58 million shsAverage Volume1.27 million shsMarket Capitalization$1.38 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Cerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD. Read More Receive CERC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cerecor and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CERC Stock News HeadlinesAytu BioPharma Stock (NASDAQ:AYTU) Insider TradesDecember 19, 2023 | benzinga.commTOR Inhibitors Global Market Report 2023August 24, 2023 | uk.finance.yahoo.comJeff Brown and Marc Chaikin's latest AI prediction explainedJeff Brown and Marc Chaikin - the duo who identified Nvidia a decade ago - are forecasting that Elon Musk's AI breakthrough they call 'M.A.G.I.' will collide with a rare market pattern by July 30. That pattern carries a 100% historical track record. The last time it triggered, early investors had a chance to turn $10,000 into as much as $350,000 in roughly 12 months. | Brownstone Research (Ad)DelveInsight Highlights Major Advances, Transformative Therapies, and 80+ Leading Players Wheeling the Crohn's Disease Pipeline LandscapeMay 11, 2023 | finance.yahoo.comEdited Transcript of AYTU.OQ earnings conference call or presentation 27-Sep-22 8:30pm GMT - Yahoo FinanceSeptember 28, 2022 | finance.yahoo.comAytu BioPharma, Inc. (AYTU) CEO Josh Disbrow on Q4 2022 Results - Earnings Call Transcript - Seeking AlphaSeptember 28, 2022 | seekingalpha.comDiGeorge Syndrome Drug Market In-Depth Analysis Research Report 2029August 31, 2022 | marketwatch.comValenzaBio Appoints Industry Veteran Peter Greenleaf to its Board of Directors - StreetInsider.comAugust 24, 2022 | streetinsider.comSee More Headlines CERC Stock Analysis - Frequently Asked Questions How were Cerecor's earnings last quarter? Cerecor Inc. (NASDAQ:CERC) released its quarterly earnings results on Sunday, August, 1st. The company reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by $0.01. The business earned $3.36 million during the quarter. Cerecor had a negative net margin of 1,194.82% and a negative trailing twelve-month return on equity of 261.82%. What other stocks do shareholders of Cerecor own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cerecor investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), OPKO Health (OPK), VBI Vaccines (VBIV), Pfizer (PFE) and Agile Therapeutics (AGRX). Company Calendar Last Earnings8/01/2021Today7/13/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:CERC CIK1534120 Webwww.cerecor.com Phone(410) 522-8707FaxN/AEmployees31Year Founded2011Profitability EPS (Trailing Twelve Months)($0.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$63.50 million Net Margins-1,194.82% Pretax MarginN/A Return on Equity-261.82% Return on Assets-133.96% Debt Debt-to-Equity Ratio0.79 Current Ratio2.19 Quick Ratio2.18 Sales & Book Value Annual Sales$6.70 million Price / Sales206.49 Cash FlowN/A Price / Cash FlowN/A Book Value$0.22 per share Price / Book65.50Miscellaneous Outstanding Shares96,009,000Free FloatN/AMarket Cap$1.38 billion OptionableNot Optionable Beta1.44 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:CERC) was last updated on 7/14/2026 by MarketBeat.com Staff. From Our PartnersSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThey told you not to miss this oneThe largest companies in the SP 500 are now more overvalued relative to fundamentals than they were at the abs...Thor Metals | SponsoredForget SpaceX, this is Elon’s Next BreakthroughJeff Brown and Marc Chaikin - two investors who called Nvidia a decade ago - say Elon Musk's newly filed AI pa...Brownstone Research | SponsoredWhen I found Rolls-Royce under $2, most people thought I was crazyIn 2022, Karim Rahemtulla recommended Rolls-Royce when it traded under $2. The stock climbed more than 1,100% ...Monument Traders Alliance | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredBofA: Digital Dollar Coming 2025-2030Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerecor Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cerecor With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
